DBV Technologies - ADR

NASDAQ:DBVT   3:59:07 PM EDT
9.16
+0.28 (+3.15%)
4:00:18 PM EDT: $9.15 -0.01 (-0.11%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)250.46M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.73 Million
Adjusted EPS-$0.18
See more estimates
10-Day MA$9.02
50-Day MA$9.21
200-Day MA$5.43
See more pivots

DBV Technologies - ADR Stock, NASDAQ:DBVT

177-181, avenue Pierre Brossolette, 107 avenue de la Republique, Chatillon, Hauts-de-France 92320
France
Phone: +33.1.55.42.78.78
Number of Employees: 104

Description

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, St�©phane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.